{"classes":[{"categories":[{"measurements":[{"groupId":"OG003","spread":"340000","value":"803200"},{"groupId":"OG004","spread":"1022000","value":"2662000"},{"groupId":"OG005","spread":"6863000","value":"9648000"},{"groupId":"OG006","spread":"3342000","value":"32420000"},{"groupId":"OG007","spread":"3413000","value":"69890000"},{"groupId":"OG008","spread":"11890000","value":"36810000"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"7"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Flat dose level; 0.15mg (Dose Level 1)","id":"OG000","title":"Part A Dose Level 1 NM21-1480-Q2W 0.15mg"},{"description":"Flat dose level; 1.5mg (Dose Level 2)","id":"OG001","title":"Part A Dose Level 2 NM21-1480-Q2W 1.5mg"},{"description":"Flat dose level; 8mg (Dose Level 3)","id":"OG002","title":"Part A Dose Level 3 NM21-1480-Q2W 8mg"},{"description":"Flat dose level; 24mg (Dose Level 4)","id":"OG003","title":"Part A Dose Level 4 NM21-1480-Q2W 24mg"},{"description":"Flat dose level; 80mg (Dose Level 5)","id":"OG004","title":"Part A Dose Level 5 NM21-1480-Q2W 80mg"},{"description":"Flat dose level; 240mg (Dose Level 6)","id":"OG005","title":"Part A Dose Level 6 NM21-1480-Q2W 240mg"},{"description":"Flat dose level; mg800 (Dose Level 7)","id":"OG006","title":"Part A Dose Level 7 NM21-1480-Q2W 800mg"},{"description":"This part of the study consisted of a 1400mg flat dose across one cohort.","id":"OG007","title":"Part A2 NM21-1480-Q2W"},{"description":"This part of the study consisted of a 800mg flat dose across three cohorts.","id":"OG008","title":"Part B NM21-1480-Q2W"}],"paramType":"MEAN","populationDescription":"AUCtau determined at C1 for all dose levels with the exception of Part A Dose Level 1, Part A Dose Level 2 and Part A Dose Level 3. Lower limit of quantification (LLOQ) of NM21-1480 = 5 ng/mL.","reportingStatus":"POSTED","timeFrame":"From baseline to up to 12 weeks post last dose, up to 48 weeks.","title":"Assessment of the Area Under Serum Concentration-time Curve Over Dosing Interval (AUCtau)","type":"SECONDARY","unitOfMeasure":"h*ng/mL"}